Some driver gene mutations, including epidermal growth factor receptor (
EGFR
), have been reported to be involved in expression regulation of the immunosuppressive checkpoint protein programmed cell death ligand 1 (
PD
‐L1), but the underlying mechanism remains obscure. We investigated the potential role and precise mechanism of
EGFR
mutants in
PD
‐L1 expression regulation in non‐small‐cell lung cancer (
NSCLC
) cells. Examination of pivotal
EGFR
signaling effectors in 8
NSCLC
cell lines indicated apparent associations between
PD
‐L1 overexpression and phosphorylation of
AKT
and
ERK
, especially with increased protein levels of phospho‐IκBα (p‐IκBα) and hypoxia‐inducible factor‐1α (HIF‐1α). Flow cytometry results showed stronger membrane co‐expression of
EGFR
and
PD
‐L1 in
NSCLC
cells with
EGFR
mutants compared with cells carrying WT
EGFR
. Additionally, ectopic expression or depletion of
EGFR
mutants and treatment with
EGFR
pathway inhibitors targeting
MEK
/
ERK
,
PI
3K/
AKT
,
mTOR
/S6, IκBα, and
HIF
‐1α indicated strong accordance among protein levels of
PD
‐L1, p‐IκBα, and
HIF
‐1α in
NSCLC
cells. Further treatment with pathway inhibitors significantly inhibited xenograft tumor growth and p‐IκBα,
HIF
‐1α, and
PD
‐L1 expression of
NSCLC
cells carrying
EGFR
mutant in nude mice. Moreover, immunohistochemical analysis revealed obviously increased protein levels of p‐IκBα,
HIF
‐1α, and
PD
‐L1 in
NSCLC
tissues with
EGFR
mutants compared with tissues carrying WT
EGFR
. Non‐small‐cell lung cancer tissues with either p‐IκBα or
HIF
‐1α positive staining were more likely to possess elevated
PD
‐L1 expression compared with tissues scored negative for both p‐IκBα and
HIF
‐1α. Our findings showed important roles of phosphorylation activation of
AKT
and
ERK
and potential interplay and cooperation between
NF
‐κB and
HIF
‐1α in
PD
‐L1 expression regulation by
EGFR
mutants in
NSCLC
.